DealFlow: Biopharma Deals This Week June 22–28, 2026

AbbVie is buying Apogee for about $10.9 billion, a 49% premium to where the stock closed on June 18. The prize is zumilokibart, a half-life-extended anti–IL-13 antibody heading into Phase III for atopic dermatitis exactly the kind of long-acting immunology asset AbbVie needs as it builds beyond Humira.

One megadeal is a transaction. Two in five days is a signal. Days earlier, Merck KGaA agreed to take Bio-Techne for $11.3 billion. After eighteen months of large-cap caution, two eleven-figure checks in a single week is the clearest sign yet that big pharma has decided it would rather buy growth than wait for it and a 49% premium is the price of conviction, not opportunism.

SK Biopharmaceuticals licensed Insilico’s AI-designed CNS programs in a deal headlined at $2.57 billion. Read the structure: $4.5 million upfront, up to $13.5 million near-term, and the remaining ~99.8% strung across milestones that may never be paid.

That gap is the story and it’s everywhere this week. AI-enabled discovery showed up in eight of fifty-eight deals, with Novartis, Lilly, Bayer and SK all writing partnership checks. The platform thesis has won. But the committed-versus-headline spread is how you separate real belief from optionality dressed as a blockbuster. When you read “$2.6 billion,” ask what cleared today.

The counter-example landed the same week. Novartis optioned Antares’ small-molecule programs against historically undruggable cancer targets,$105 million upfront against up to $1.8 billion in milestones. At roughly 6% of headline value committed on day one, Novartis is putting down more than twenty times the upfront share SK placed behind Insilico.

Same AI-discovery thesis, very different level of belief. For ranking this week’s platform deals, upfront cash is the honest scoreboard,it’s the number a partner can’t walk back. Antares, backed by Atlas and Lightspeed, just drew the strongest vote of the cohort.

Lilly took worldwide rights to Abbisko’s discovery programs in a deal worth up to $1.9 billion, its second licensing deal of the week, after a separate $800M pact with Sweden’s BioArctic. Lilly’s 2026 deal count now stands at 16 licensing agreements and 11 acquisitions and divestitures, with total disclosed value exceeding $55 billion. Abbisko is one of four Chinese biotechs that out-licensed to Western buyers in five days, alongside Haisco (to Nuvectis, $1.46B), TrueLab (to Bionyra, $985M) and CStone (to Arrotex).

The direction of travel is now unmistakable: China has moved from making the industry’s chemistry to originating its molecules, and global pharma is the buyer of record. Four outbound deals in one week isn’t a blip it’s the emerging supply chain for early-stage innovation.

Read the full Lilly breakdown →

Serapha Bio is going public by reverse-merging into Boundless Bio, taking the ticker AATD to fund its base-editing program for alpha-1 antitrypsin deficiency paired with a ~$230 million private placement led by RTW and RA Capital. It wasn’t alone: Remix Therapeutics ran the identical play into Passage Bio the same week, also with a concurrent raise.

When two companies pick a shell over an S-1 in five days, and both bring their own money, the read is plain the traditional biotech IPO window hasn’t reopened. For now, reverse merger plus PIPE is how quality assets are getting public. A structural signal worth carrying into the second half.